Glyxambi is owned by Boehringer Ingelheim.
Glyxambi contains Empagliflozin; Linagliptin.
Glyxambi has a total of 13 drug patents out of which 0 drug patents have expired.
Glyxambi was authorised for market use on 30 January, 2015.
Glyxambi is available in tablet;oral dosage forms.
Glyxambi can be used as method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin, method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin, method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin, method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin, method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without insulin or a sulfonylurea); method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without metformin).
The generics of Glyxambi are possible to be released after 11 June, 2034.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(2 years from now) | |
US7713938 | BOEHRINGER INGELHEIM | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Apr, 2027
(4 years from now) | |
US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(5 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8119648 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(6 months from now) | |
US8178541 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(6 months from now) | |
US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(2 years from now) | |
US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(4 years from now) | |
US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(4 years from now) | |
US11033552 | BOEHRINGER INGELHEIM | DPP IV inhibitor formulations |
May, 2027
(4 years from now) | |
US8551957 | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Oct, 2029
(6 years from now) | |
US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(11 years from now) | |
US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(11 years from now) | |
US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Jul 3, 2022 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
Market Authorisation Date: 30 January, 2015
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without insulin or a sulfonylurea); Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without metformin); Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic